Proof-of-concept phase I trial of ACH 3422 in patients with chronic hepatitis C

Trial Profile

Proof-of-concept phase I trial of ACH 3422 in patients with chronic hepatitis C

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2015

At a glance

  • Drugs ACH 3422 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 05 Mar 2015 Results are anticipated during the second quarter of 2015, according to an Achillion Pharmaceuticals media release.
    • 05 Mar 2015 Planned initiation date changed from 1 Jul 2014 to 1 Mar 2015, according to an Achillion Pharmaceuticals media release.
    • 14 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top